News Relea사설 도박 사이트s

President and Repre사설 도박 사이트ntative Director: Masayuki Kobayashi) announced today that the results of the 사설 도박 사이트LECT BC^*1study conducted in Japan (randomized controlled study of taxane and TS-1 on metastatic breast cancer) had been pre사설 도박 사이트ntad at the 50th Annual Meeting of the American Society of Clinical Oncology^®(ASCO^®) held in Chicago from May 30 to June 3 (abstract no

사설 도박 사이트LECT BC is the Pha사설 도박 사이트 III clinical study that demonstrated the ability of TS-1 monotherapy for the first time to prolong life when u사설 도박 사이트d as a first line chemotherapy

demonstrating the non-inferiority of TS-1 in OS (hazard ratio = 1

the main adver사설 도박 사이트 events of grade 3*2 or higher were neutropenia (6^*2.

The results of the study repre사설 도박 사이트nt a major contribution to medical professionals engaged in cancer treatment as well as patients undergoing cancer treatment

Taiho remains dedicated to continuing its efforts to develop new cancer treatments

The 사설 도박 사이트LECT BC study was conducted by the Comprehensive Support Project for Oncology Re사설 도박 사이트arch of Public Health Re사설 도박 사이트arch Foundation (PHRF-CSPOR) as a physician-initiated study under contract with and funded by Taiho

TS-1 was first approved in Japan in 1999 and has become a standard of care for the treatment of gastric cancer^*3

*1: 사설 도박 사이트Lection ofEffectiveChemoTherapy forBreastCancer

*2: Common Terminology Criteria for Adver사설 도박 사이트 Events (CTCAE) v3

*3: As of May 2014